<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04235621</url>
  </required_header>
  <id_info>
    <org_study_id>GFB-887-501</org_study_id>
    <nct_id>NCT04235621</nct_id>
  </id_info>
  <brief_title>A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)</brief_title>
  <official_title>A Study to Characterize the Genetic, Biomarker, and Clinical Profile of Patients With Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Goldfinch Bio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Goldfinch Bio, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study with 2 parts. Part 1 comprises a visit to collect biological samples&#xD;
      necessary for the molecular characterization of chronic kidney disease. Part 2 comprises an&#xD;
      observational period of 5 visits over a period up to 8 weeks. During Part 2, baseline tests&#xD;
      will be conducted, and urine will be collected approximately every 2 weeks for 8 weeks.&#xD;
      Patients may participate in Part 1, Part 2, or both, and will be followed for up to 1 year&#xD;
      consisting of data collection from the patient's medical records and home collection of urine&#xD;
      samples every 4 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor decision for administrative reasons&#xD;
  </why_stopped>
  <start_date type="Actual">December 20, 2019</start_date>
  <completion_date type="Actual">May 27, 2020</completion_date>
  <primary_completion_date type="Actual">May 27, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Urine Protein-to-Creatinine Ratio (UPCR)</measure>
    <time_frame>Approximately 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Urine Albumin-to-Creatinine Ratio (UACR)</measure>
    <time_frame>Approximately 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimated Glomerular Filtration Rate (eGFR)</measure>
    <time_frame>Baseline/Biomarker collection visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Estimated Glomerular Filtration Rate (eGFR)</measure>
    <time_frame>Approximately 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Urine Biomarker: Nephrin</measure>
    <time_frame>Approximately 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Urine Biomarker: Podocin</measure>
    <time_frame>Approximately 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Urine Biomarker: Rac1</measure>
    <time_frame>Approximately 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Urine Biomarker: Synaptopodin</measure>
    <time_frame>Approximately 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Urine Biomarker: Urea</measure>
    <time_frame>Approximately 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Urine Biomarker: Other Exploratory</measure>
    <time_frame>Approximately 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Serum/Plasma Biomarker: Other Exploratory</measure>
    <time_frame>Approximately 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with genetic variants predicted to be associated with chronic kidney disease and functional consequence</measure>
    <time_frame>Baseline/Biomarker collection visit</time_frame>
    <description>DNA analysis of blood sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gene expression profile and phenotype of inducible pluripotent stem cell (iPSC)-generated organoids</measure>
    <time_frame>Baseline/Biomarker collection visit</time_frame>
    <description>Generation of iPSC from whole blood sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline Patient-reported Assessment of FSGS Symptoms</measure>
    <time_frame>Approximately 8 weeks</time_frame>
    <description>FSGS/TR-MCD patients will assess disease symptomatology utilizing the FSGS Symptom Diary and FSGS Symptom Impact Questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline Patient-reported Assessment of Health Status</measure>
    <time_frame>Approximately 8 weeks</time_frame>
    <description>Patients will assess health status using the 36-Item Short Form Health Survey (SF-36)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline Patient-reported Assessment of Fatigue</measure>
    <time_frame>Approximately 8 weeks</time_frame>
    <description>Patients will assess the symptom of fatigue utilizing the Modified Fatigue Impact Scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline Clinician-reported Assessment of Edema</measure>
    <time_frame>Approximately 8 weeks</time_frame>
    <description>Clinicians will assess edema in FSGS/TR-MCD patients using a standardized measurement of edema in FSGS/TR-MCD patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Untoward Medical Occurrences</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Incidence of untoward medical occurrences that result in death; are life threatening; require inpatient hospitalization or prolongation of existing hospitalization; result in persistent or significant disability/incapacity; results in a congenital anomaly/birth defect; or result in an important medical event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>% of Patients with Change in Treatment</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Change in treatment as indicated by patient medical record</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">20</enrollment>
  <condition>Glomerulosclerosis, Focal Segmental</condition>
  <condition>Minimal Change Disease</condition>
  <condition>Diabetic Nephropathies</condition>
  <arm_group>
    <arm_group_label>FSGS/TR-MCD</arm_group_label>
    <description>Patients with FSGS/TR-MCD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetic Nephropathy (DN)</arm_group_label>
    <description>Patients with DN</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>FSGS/TR-MCD</intervention_name>
    <description>This is a non-interventional study</description>
    <arm_group_label>FSGS/TR-MCD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diabetic Nephropathy (DN)</intervention_name>
    <description>This is a non-interventional study</description>
    <arm_group_label>Diabetic Nephropathy (DN)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be drawn from participating investigators' clinics&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For FSGS/TR-MCD patients :&#xD;
&#xD;
          1. Competent and willing to provide informed consent and adhere to all study assessments&#xD;
             and restrictions.&#xD;
&#xD;
          2. Male or female ≥ 18 years of age with FSGS or TR-MCD at the time of providing written&#xD;
             informed consent.&#xD;
&#xD;
          3. Diagnosis of FSGS or TR-MCD, based on either biopsy or genetic testing.&#xD;
&#xD;
          4. Urinary protein to creatinine ratio (UPCR) ≥ 1.0 g/g.&#xD;
&#xD;
          5. Estimated glomerular filtration rate (eGFR) ≥ 45 mL/min/1.73 m2.&#xD;
&#xD;
        For DN patients:&#xD;
&#xD;
          1. Competent and willing to provide informed consent and adhere to all study assessments&#xD;
             and restrictions.&#xD;
&#xD;
          2. Male or female ≥ 18 years of age with DN at the time of providing written informed&#xD;
             consent.&#xD;
&#xD;
          3. Diagnosis of type 2 diabetes&#xD;
&#xD;
          4. Urinary albumin to creatinine ratio (UACR) ≥ 150 mg/g.&#xD;
&#xD;
          5. Estimated glomerular filtration rate (eGFR) ≥ 45 mL/min/1.73 m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        For FSGS/TR-MCD patients:&#xD;
&#xD;
          1. Evidence of another kidney disease or kidney disease secondary to an infectious&#xD;
             process.&#xD;
&#xD;
          2. History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C. Patients&#xD;
             whose results are compatible with prior immunization or treatment may be included.&#xD;
&#xD;
          3. Body mass index (BMI) &gt; 42 kg/m2.&#xD;
&#xD;
          4. Significant history or evidence of clinically significant disorder, condition, current&#xD;
             illness, or disease that, in the opinion of the Investigator, would pose a risk to&#xD;
             patient safety or interfere with the study evaluation, procedures, or completion (eg,&#xD;
             severe cardiac disease, cardiac conduction defect, or severe or chronic hepatobiliary&#xD;
             disease).&#xD;
&#xD;
          5. History of malignancy not in remission within the last 5 years other than adequately&#xD;
             treated basal cell or squamous cell skin cancer or cervical carcinoma in situ.&#xD;
&#xD;
          6. History of any organ or bone marrow transplant, including kidney grafts.&#xD;
&#xD;
          7. History of alcoholism or drug/chemical abuse within 12 months.&#xD;
&#xD;
          8. Preplanned surgery or procedures that would interfere with the conduct of the study.&#xD;
&#xD;
        For DN patients:&#xD;
&#xD;
          1. Evidence of another kidney disease or kidney disease secondary to an infectious&#xD;
             process.&#xD;
&#xD;
          2. History of HIV, hepatitis B, or hepatitis C. Patients whose results are compatible&#xD;
             with prior immunization or treatment may be included.&#xD;
&#xD;
          3. BMI &gt; 42 kg/m2.&#xD;
&#xD;
          4. Significant history or evidence of clinically significant disorder, condition, current&#xD;
             illness, or disease that, in the opinion of the Investigator, would pose a risk to&#xD;
             patient safety or interfere with the study evaluation, procedures, or completion (eg,&#xD;
             severe cardiac disease, cardiac conduction defect, or severe or chronic hepatobiliary&#xD;
             disease).&#xD;
&#xD;
          5. History of malignancy not in remission within the last 5 years other than adequately&#xD;
             treated basal cell or squamous cell skin cancer or cervical carcinoma in situ.&#xD;
&#xD;
          6. History of any organ or bone marrow transplant, including kidney grafts.&#xD;
&#xD;
          7. History of alcoholism or drug/chemical abuse within 12 months.&#xD;
&#xD;
          8. Preplanned surgery or procedures that would interfere with the conduct of the study.&#xD;
&#xD;
          9. Renal disease that requires immunosuppressive therapy (currently, or in the past).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Aventiv Research - Phoenix</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85210-6041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glendale Adventist Medical Center</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Mojave Sage Dialysis</name>
      <address>
        <city>Victorville</city>
        <state>California</state>
        <zip>92395-8322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Kidney Care</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230-7200</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renal and Transplant Associates of New England, PC</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107-1369</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Clair Nephrology</name>
      <address>
        <city>Roseville</city>
        <state>Michigan</state>
        <zip>48066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404-1212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consultants</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Pelican Point Dialysis</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89129-6201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>High Desert Nephrology</name>
      <address>
        <city>Gallup</city>
        <state>New Mexico</state>
        <zip>87301-5655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akron Nephrology Associates, Inc.</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44302-1715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Renal Research Institute</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404-2743</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arlington Nephrology, PC</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Texas Kidney Disease Association</name>
      <address>
        <city>Lewisville</city>
        <state>Texas</state>
        <zip>75057-6039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Renal Care Group (Downtown)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Antonio Kidney Disease Center Physicians Group (Wurzbach Road)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Renal Care Group (Westover Hills)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78251-1230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Antonio Kidney Disease Center Physicians Group (Carnoustie Drive)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258-4800</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 31, 2019</study_first_submitted>
  <study_first_submitted_qc>January 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2020</study_first_posted>
  <last_update_submitted>July 17, 2021</last_update_submitted>
  <last_update_submitted_qc>July 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Glomerulosclerosis, Focal Segmental</mesh_term>
    <mesh_term>Nephrosis, Lipoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient reported outcome (and other relevant data) will be shared with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

